Alzheimer
Beyond's analysis on Alzheimer
- — FDA approves subcutaneous Leqembi for early Alzheimer’s, enabling once‑weekly dosing
- — FDA’s approval of a subcutaneous starting dose for Leqembi Iqlik opens a new at‑home dosing option for early Alzheimer’s, potentially expanding patient access and driving uptake of Eisai‑BioArctic’s anti‑amyloid therapy
- — Eisai’s subcutaneous Leqembi data signal a user‑friendly alternative that could widen the Alzheimer’s drug market and boost partner BioArctic’s revenues
- — Leqembi’s subcutaneous autoinjector shows comparable efficacy and safety to IV form, potentially widening patient access
- — Europe faces mounting pressure to modernize Alzheimer’s care as 20 million people live with the disease
Recent news mentioning Alzheimer
- — CaringKind and UsAgainstAlzheimer's Collaborate to Offer Advocacy Opportunities for 100 Women of Impact
- — Medicare Advantage patients who get diagnosed with Alzheimer’s or other serious diseases are ditching their plans — and it can cost them
- — Visiting Angels Sets $1 Million+ Fundraising Goal for 2026 Walk to End Alzheimer's
- — Ashley Williams and Nikki DeLoach to Host Annual Dance Party to End ALZ Benefiting the Alzheimer's Association
- — Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's
- — Anavex Life Sciences Advances Alzheimer’s Phase 3 Planning as Cash Runway Extends Into Fiscal 2028
- — LEQEMBI IQLIK®(lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease
- — Quest Diagnostics to Offer FDA-Cleared Roche pTau217 Blood Test to Assess Alzheimer's Disease Pathology
- — Labcorp to Offer First FDA-Cleared Blood Test to Detect Alzheimer's Disease Pathology in Both Primary and Specialty Care Settings
- — Roche receives FDA clearance for Elecsys® pTau217, advancing Alzheimer's disease assessment across primary and specialty care
- — FDA Clearance of C2N Diagnostics' PrecivityAD2 Blood Test Advances Precision Medicine for Alzheimer's, Building on Groundwork Laid by Early ADDF Investment
- — CURE ALZHEIMER'S FUND APPOINTS NEW EXECUTIVE VICE PRESIDENT OF MARKETING AND COMMUNICATIONS